COMMUNIQUÉS West-GlobeNewswire

Tetra Bio-Pharma’s Management Post Financing Corporate Update
18/07/2019
Drug portfolio with U.S. granted patent protection for ophthalmic use, drug solubility and abuse deterrence; U.S. FDA provides positive response on painful dry eye development program; Panag completes a Phase 3 clinical [...]
UK Confirms its Leadership Position in Advanced Therapies
18/07/2019
UK Confirms its Leadership Position in Advanced Therapies Cell and gene therapies and tissue-engineered products have the potential to offer a durable, life-changing effect, possibly with single administration New [...]
Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report
18/07/2019
AMF REGULATED INFORMATION Montrouge, France, July 18, 2019 Amendment to the DBV Technologies Liquidity Contract with NATIXIS ODDO BHF and Half-Year Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq [...]
Avenant et Bilan semestriel du contrat de liquidité DBV Technologies avec NATIXIS ODDO BHF
18/07/2019
Informations Réglementées Montrouge, France, le 18 juillet (7h30 CET), 2019 Avenant et Bilan semestriel du contrat de liquidité DBV Technologies avec NATIXIS ODDO BHF DBV Technologies (Euronext : DBV – ISIN : [...]
Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased
18/07/2019
Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +81% (cc) with increased [...]
Novartis au 2e trimestre: fortes ventes, croissance à deux chiffres du résultat opérationnel core et lancements de Zolgensma et de Piqray; prévision des ventes et du résultat revue à la hausse
18/07/2019
Chiffre d'affaires net des activités poursuivies[1] en hausse de 8% (tcc[2], +4% USD) soutenu par: Cosentyx : USD 858 millions, +25% (tcc) stimulé principalement par le maintien de la forte croissance aux Etats-Unis (+ [...]
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis
18/07/2019
Orphazyme A/S Company announcement No. 17/2019 Company Registration No. 32266355 • Headline results from full analysis expected in H1 2021 Copenhagen, Denmark, July 18, 2019 – Orphazyme A/S (ticker: ORPHA.CO), a [...]
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
18/07/2019
Geneva, Switzerland and Boston, MA – July 18, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for [...]
Pixium Vision announced sustained success of its PRIMA System after 12-months in dry age-related macular degeneration patients
18/07/2019
Data confirm better than expected interim six-month results The system is sustainably well tolerated while preserving residual peripheral vision Some patients improve their ability to identify letters and sequence of [...]
Pixium Vision confirme les bons résultats cliniques de son système Prima après 12 mois chez des patients atteints de DMLA sèche
18/07/2019
Les données renforcent les résultats intermédiaires meilleurs qu’attendus à 6 mois Le système est toujours bien toléré et sans impact sur la vision périphérique résiduelle Plusieurs patients améliorent leur capacité à [...]
Acacia Pharma Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession
18/07/2019
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 18 July 2019: Acacia Pharma Group plc (“Acacia Pharma”, [...]
Fulcrum Therapeutics Announces Pricing of Initial Public Offering
18/07/2019
CAMBRIDGE, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (the “Company”) (Nasdaq:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically [...]
Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs) in the United States
18/07/2019
Company Announcement Genmab has today announced the pricing of its initial public offering of ADSs and the listing of the ADSs on the Nasdaq Global Select Market under the symbol “GMAB” Genmab has applied to change the [...]
Forty Seven, Inc. Prices Underwritten Public Offering of 9,375,000 Shares of Common Stock
18/07/2019
MENLO PARK, Calif., July 17, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of 9 [...]
H-CYTE Comments on Recent Promotional Activity
17/07/2019
TAMPA, Fla., July 17, 2019 (GLOBE NEWSWIRE) -- H-CYTE, INC. (OTCQB: HCYT), wishes to make, at the request of the OTC Markets Group Inc., the following release regarding certain market activity surrounding the Company's [...]
Innovate Phytotechnologies Inc. Hemp for Life(TM) Products Hit the Market in America
17/07/2019
VANCOUVER, B.C. and KELOWNA, B.C., July 17, 2019 (GLOBE NEWSWIRE) -- Innovate Phytotechnologies Inc., through its wholly owned subsidiary, Phytomatrix Natural Technologies Inc., (“Phytomatrix”) is pleased to announce [...]
Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17/07/2019
WALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors granted a new employee [...]
AzurRx BioPharma Announces Proposed Public Offering of Common Stock
17/07/2019
BROOKLYN, N.Y., July 17, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), announced today that it intends to offer and sell shares of its common stock in an underwritten public [...]
Micron Solutions, Inc. Hires New CFO
17/07/2019
FITCHBURG, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Micron Solutions, Inc. (NYSE American: MICR) (the “Company”), a diversified contract manufacturing organization, through its wholly-owned subsidiary, Micron Products, [...]

Pages